So sánh phương pháp
Xem các phương pháp đã chọn cạnh nhau; những hàng khác biệt được làm nổi bật.
| Chỉ số Diện tích và Mức độ Nghiêm trọng Vảy nến (PASI)× | EASI (Chỉ số mức độ và diện tích bệnh chàm)× | Chỉ số SCORAD (SCORing Atopic Dermatitis)× | |
|---|---|---|---|
| Lĩnh vực | Da liễu học | Da liễu học | Da liễu học |
| Họ | Process / pipeline | Process / pipeline | Process / pipeline |
| Năm ra đời≠ | 1978 | 2001 | 1993 |
| Người khởi xướng≠ | Fredriksson T, Pettersson U | Hanifin JM, Thurston M | European Task Force on Atopic Dermatitis (ETFAD) |
| Loại | Clinician-rated | Clinician-rated | Clinician-rated |
| Công trình gốc≠ | Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-244. DOI ↗ | Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Experimental Dermatology. 2001;10(1):11-18. DOI ↗ | Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10-19. DOI ↗ |
| Tên gọi khác | PASI Index | EASI Index | SCORAD Index |
| Liên quan≠ | 2 | 2 | 3 |
| Tóm tắt≠ | The PASI is the gold-standard clinician-administered measure of psoriasis severity and extent. Developed by Fredriksson and Pettersson in 1978, it evaluates four cardinal clinical signs (erythema, induration, desquamation) across four body regions, each weighted by anatomical importance. PASI is the most widely used endpoint in psoriasis clinical trials and is endorsed by regulatory agencies (FDA, EMA) and international dermatology societies. | The EASI is a structured, clinician-administered tool for assessing the extent and intensity of atopic dermatitis across the body. Developed by Hanifin and colleagues in 2001, it divides the body into four regions with weighted area factors, ensuring proportional contribution to total score. EASI has become the primary objective severity measure in atopic dermatitis clinical trials and is recommended by international regulatory authorities (FDA, EMA). | The SCORAD is a comprehensive clinician-administered tool for measuring the extent and severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis in 1993, it combines objective clinical assessment with subjective symptom reporting. It is the gold standard for atopic dermatitis severity in clinical trials and dermatology practice. |
| ScholarGateBộ dữ liệu ↗ |
|
|
|